Clinical Trial Update: An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD [Phase 3]

View source ↗

Summary

An extension study evaluating the long-term safety and efficacy of pegcetacoplan (APL-2) in geographic atrophy due to age-related macular degeneration; the tria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Geographic Atrophy

Drugs mentioned

• Pegcetacoplan (Pegcetacoplan)

Snippet

Sponsor: Apellis Pharmaceuticals, Inc. | Conditions: Geographic Atrophy Secondary to Age-related Macular Degeneration | Phase 3 | Status: COMPLETED